A live webcast of the presentation will be available from the Investor Relations section of the company website at Events & Presentations - Bellicum with a replay available shortly after the live event.
About
Bellicum is a clinical stage biopharmaceutical company striving to deliver cures through controllable cell therapies. The company’s next-generation product candidates are differentiated by powerful cell signaling technologies designed to produce more effective CAR-T cell therapies. Bellicum’s GoCAR-T® product candidates, BPX-601 and BPX-603, are designed to be more efficacious CAR-T cell products capable of overriding key immune inhibitory mechanisms. More information about Bellicum can be found at www.bellicum.com or follow us on Twitter or LinkedIn.
Investors:
Managing Director
ICR Westwicke
858-356-5932
Robert.uhl@westwicke.com
![](https://ml.globenewswire.com/media/N2UwODVkNTgtZjkzNC00NGExLTk5ZmEtYWU1ODYzYmJjNDZlLTEwMjgyNjg=/tiny/Bellicum-Pharmaceuticals-Inc-.png)
2022 GlobeNewswire, Inc., source